RT Journal Article
SR Electronic
T1 Decoding distinctive features of plasma extracellular vesicles in amyotrophic lateral sclerosis
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.08.06.20169300
DO 10.1101/2020.08.06.20169300
A1 Pasetto, Laura
A1 Callegaro, Stefano
A1 Ferrara, Deborah
A1 Brunelli, Laura
A1 Sestito, Giovanna
A1 Pastorelli, Roberta
A1 Bianchi, Elisa
A1 Corbelli, Alessandro
A1 Fiordaliso, Fabio
A1 Cretich, Marina
A1 Chiari, Marcella
A1 Potrich, Cristina
A1 Moglia, Cristina
A1 Corbo, Massimo
A1 Sorarù, Gianni
A1 Lunetta, Christian
A1 Calvo, Andrea
A1 Chiò, Adriano
A1 Mora, Gabriele
A1 Pennuto, Maria
A1 Quattrone, Alessandro
A1 Rinaldi, Francesco
A1 D’Agostino, Vito
A1 Basso, Manuela
A1 Bonetto, Valentina
YR 2020
UL http://medrxiv.org/content/early/2020/08/12/2020.08.06.20169300.abstract
AB Amyotrophic lateral sclerosis is a multifactorial and multisystem motor neuron disease with currently no effective treatment. There is an urgent need to identify biomarkers that can tackle the disease’s complexity and help in early diagnosis, prognosis, and therapy development. Extracellular vesicles (EVs) are nanostructures that are released by any cell type into body fluids. Their variable biophysical and biochemical characteristics reflect the parent cell’s physiological and pathological state and make them an attractive source of multidimensional data for patient classification and stratification. To test whether EVs could be exploited as diagnostic and prognostic biomarkers in ALS, we analyzed plasma-derived EVs of ALS patients and relative healthy and diseased controls. Using the nickel-based isolation, a recently developed EV purification method, we unmasked peculiar features in plasma EVs of ALS patients with a potential straightforward application in a clinical setting. We report that the number of particles is increased in the plasma of ALS patients and two mouse models of ALS while the average diameter is decreased. Proteins like HSP90 and phosphorylated TDP-43 are differentially represented in ALS patients and mice compared to the controls. In terms of disease progression, the levels of phosphorylated TDP-43 and cyclophilin A, along with the EV size distribution, discriminated fast and slow disease progressors suggesting a new means for patient stratification. Finally, we conceived an innovative mathematical model based on machine learning techniques that integrating EV size distribution data with biochemical EV parameters resulted in very high prediction rates for disease diagnosis and prognosis.Competing Interest StatementVDA and AQ declare competing interests for the patent application of the NBI procedure (WO2019122003).Funding StatementThis study has been supported by grants listed in the relative paragraph of the textAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All experiments have been conducted upon approval.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData availability All the data generated for this manuscript are available upon requests to the corresponding authors. Proteomics The whole mass spectrometry proteomics data have been deposited to the ProteomeXchange Consortium (http://proteomecentral.proteomexchange.org/cgi/GetDataset) via the PRIDE partner repository with the data set identifier PXD020629